Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment
Table 3
Data on exclusivity following approval of biosimilars.
Country
Data on exclusivity period
Japan
Eight years of data exclusivity
Canada
Eight years of data exclusivity
United States
Four years of data exclusivity/eight years of market exclusivity
